Organon (OGN) Share-based Compensation Growth (1y) (2021 - 2026)
Organon (OGN) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Stock Comp. Growth (1y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
- |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
4.55% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
4.17% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
8.29% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-5.13% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
-11.76% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
4.31% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
60.00% |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
1.39% |
| 10 |
Organon |
3.50 Bn |
2.39 Bn |
783.00 Mn |
-20.83% |
| Date | Value |
|---|
| Mar 31, 2026 |
-20.83% |
| Dec 31, 2025 |
-73.08% |
| Sep 30, 2025 |
-4.00% |
| Jun 30, 2025 |
-21.43% |
| Mar 31, 2025 |
-7.69% |
| Dec 31, 2024 |
-3.70% |
| Sep 30, 2024 |
-7.41% |
| Jun 30, 2024 |
12.00% |
| Mar 31, 2024 |
18.18% |
| Dec 31, 2023 |
17.39% |
| Sep 30, 2023 |
50.00% |
| Jun 30, 2023 |
31.58% |
| Mar 31, 2023 |
46.67% |
| Dec 31, 2022 |
53.33% |
| Sep 30, 2022 |
20.00% |
| Jun 30, 2022 |
5.56% |
| Mar 31, 2022 |
36.36% |
| Dec 31, 2021 |
87.50% |
| Sep 30, 2021 |
36.36% |
| Jun 30, 2021 |
63.64% |
